UPMC | HILLMAN CANCER CENTER

Daratumumab (Darzalex)

About This Medicine

DARATUMUMAB (dar a toom ue mab) treats multiple myeloma, a type of bone marrow cancer. It works by helping your immune system slow or stop the spread of cancer cells. It is a monoclonal antibody. It is given in the vein (IV).

This medicine may be used for other purposes; ask your care team if you have questions.

Possible Side Effects

- Bone marrow suppression. This is a decrease in the number of white blood cells, red blood cells, and platelets. This may raise your risk of infection, make you tired and weak, and raise your risk of bleeding.
- Nausea
- Diarrhea (loose bowel movements)
- Constipation (not able to move bowels)
- Fever
- While you are getting this medicine in your vein (IV), you may have a reaction to the medicine. Sometimes you may be given medicine to stop or lessen these side effects. Your care team will check you closely for these signs: fever or shaking chills, flushing, facial swelling, feeling dizzy, headache, blurred vision or other changes in eyesight, trouble breathing, rash, itching, chest tightness, or chest pain. These reactions may happen after your infusion. **If this happens, call 911 for emergency care.**
- Tiredness and weakness
- Swelling of your legs, ankles and/or feet
- Effects on the nerves are called peripheral neuropathy. You may feel numbness, tingling, or pain in your hands and feet. It may be hard for you to button your clothes, open jars, or walk as usual. The effect on the nerves may get worse with more doses of the medicine. These effects get better in some people after the medicine is stopped but it does not get better in all people.
- Cough
- Trouble breathing
- Upper respiratory tract infection

Note: *Each of the side effects above was reported in 20% or greater of people treated with daratumumab. All possible side effects are not included. Your side effects may be different depending*

ELSEVIER

User/Authorized User acknowledges that the ClinicalPath Portal is intended to be utilized as an information management tool only, and that Elsevier has not represented the ClinicalPath Portal as having the ability to diagnose disease, prescribe treatment, or perform any other tasks that constitute the practice of providing medical care. The clinical information contained within the ClinicalPath Portal is intended as a supplement to, and not a substitute for, the knowledge, expertise, skill, and judgment of physicians, pharmacists and other healthcare professionals involved with patient care at User/Authorized User facilities. CONFIDENTIAL AND PROPRIETARY. NOT FOR DISTRIBUTION.

on your cancer diagnosis, condition, or if you are receiving other medicines in combination. Please discuss any concerns or questions with your care team.

Warnings and Precautions

- Severe infusion-related reactions to this medicine can happen, which can be life-threatening.
- Risk of severe and life-threatening infections
- This medicine can affect the results of blood tests that match your blood type during your treatment and for up to 6 months after your treatment. Your blood type will be tested before treatment. Be sure to tell all healthcare providers you are taking this medicine before receiving blood transfusions, and for 6 months after your last dose.

***Note**: Some of the side effects above are very rare. If you have concerns and/or questions, please discuss them with your care team.*

Important Information

- Reactivation of the hepatitis B virus if you have ever been exposed to the virus. This can affect your liver function and cause liver failure and be life-threatening.
- This medicine may be present in the urine, stool and other body fluids such as blood, vomit, semen, and vaginal fluids. Take precautions to prevent others from coming in contact with your medicine or your body fluids. Follow safety precautions during your treatment and for as long as directed by your care team after your treatment.
- This medicine contains sorbitol, a source of fructose. Talk to your care team if you have hereditary fructose intolerance (HFI) and cannot break down fructose.

Treating Side Effects

- Manage tiredness by pacing your activities for the day.
- Be sure to include periods of rest between energy-draining activities.
- To decrease the risk of infection, wash your hands regularly.
- Avoid close contact with people who have a cold, the flu, or other infections.
- Take your temperature as your care team tells you, and whenever you feel like you may have a fever.
- To help decrease the risk of bleeding, use a soft toothbrush. Check with your care team before using dental floss.
- Be very careful when using knives or tools.
- Use an electric shaver instead of a razor.
- Drink enough fluids to keep your urine pale yellow.
- If you throw up or have diarrhea, you should drink more fluids so that you do not become dehydrated (lack of water in the body from losing too much fluid).
- To help with nausea, eat small, frequent meals instead of three large meals a day. Choose foods and drinks that are at room temperature. Ask your care team about other helpful tips and medicine that is available to help stop or lessen these symptoms.

ELSEVIER

User/Authorized User acknowledges that the ClinicalPath Portal is intended to be utilized as an information management tool only, and that Elsevier has not represented the ClinicalPath Portal as having the ability to diagnose disease, prescribe treatment, or perform any other tasks that constitute the practice of providing medical care. The clinical information contained within the ClinicalPath Portal is intended as a supplement to, and not a substitute for, the knowledge, expertise, skill, and judgment of physicians, pharmacists and other healthcare professionals involved with patient care at User/Authorized User facilities. CONFIDENTIAL AND PROPRIETARY. NOT FOR DISTRIBUTION.

- If you have diarrhea, eat low-fiber foods that are high in protein and calories and avoid foods that can irritate your digestive tracts or lead to cramping.
- If you are not able to move your bowels, check with your care team before you use enemas, laxatives, or suppositories.
- Ask your care team about medicine that can lessen or stop your diarrhea and/or constipation.
- If you have numbness and tingling in your hands and feet, be careful when cooking, walking, and handling sharp objects and hot liquids.
- Infusion reactions may rarely occur after your infusion. **If this happens, call 911 for emergency care**.

Food and Medicine Interactions

- There are no known interactions of daratumumab with food.
- This medicine may interact with other medicines. Tell your care team about all the prescription and over-the-counter medicines and dietary supplements (vitamins, minerals, herbs, and others) that you are taking at this time. Also, check with your care team before starting any new prescription or over-the-counter medicines, or dietary supplements to make sure that there are no interactions.

When to Call Your Care Team

Call your care team if you have any of these symptoms and/or any new or unusual symptoms:

- Fever of 100.4° F (38° C) or higher
- Chills
- Tiredness and/or weakness that interferes with your daily activities
- Feeling dizzy or lightheaded
- Easy bleeding or bruising
- Cough that is bothersome and/or coughing up yellow, green, or bloody mucus
- Wheezing and/or trouble breathing
- Nausea that stops you from eating or drinking and/or is not relieved by prescribed medicines
- Throwing up more than 3 times a day
- No bowel movement in 3 days or when you feel uncomfortable
- Diarrhea, 4 times in one day or diarrhea with lack of strength or a feeling of being dizzy
- Weight gain of 5 pounds in one week (fluid retention)
- Swelling of your legs, ankles and/or feet
- Signs of infection: fever or chills, cough, trouble breathing, severe pain in your abdomen, trouble urinating, burning or pain when you pass urine, redness and/or swelling of the skin
- Signs of possible liver problems: dark urine, pale bowel movements, pain in your abdomen, feeling very tired and weak, unusual itching, or yellowing of the eyes or skin
- Signs of infusion reaction: fever or shaking chills, flushing, facial swelling, feeling dizzy, headache, trouble breathing, blurred vision or other changes in eyesight, rash, itching, chest tightness, or chest pain. **If this happens, call 911 for emergency care.**

ELSEVIER

User/Authorized User acknowledges that the ClinicalPath Portal is intended to be utilized as an information management tool only, and that Elsevier has not represented the ClinicalPath Portal as having the ability to diagnose disease, prescribe treatment, or perform any other tasks that constitute the practice of providing medical care. The clinical information contained within the ClinicalPath Portal is intended as a supplement to, and not a substitute for, the knowledge, expertise, skill, and judgment of physicians, pharmacists and other healthcare professionals involved with patient care at User/Authorized User facilities. CONFIDENTIAL AND PROPRIETARY. NOT FOR DISTRIBUTION.

- Numbness, tingling, or pain in your hands and feet

Reproduction Warnings

- **Pregnancy warning**: This medicine may cause serious birth defects. If you can become pregnant, use birth control while taking this medicine and for 3 months after the last dose. Tell your care team right away if you think you might be pregnant. When receiving daratumumab in combination with other agents, please refer to the medicine guide of those agents for more specific information.
- **Breastfeeding warning**: Talk with your care team about breastfeeding during treatment. You may need to stop breastfeeding. When receiving daratumumab in combination with other agents, please refer to the medicine guide of those agents for more specific information.
- **Fertility warning:** The effect of this medicine on fertility is not known. If you plan to have children, talk with you care team. When receiving daratumumab in combination with other agents, please refer to the medicine guide of those agents for more specific information.

Revised July 2026

Disclaimer

User/Authorized User acknowledges that the ClinicalPath Portal is intended to be utilized as an information management tool only, and that Elsevier has not represented the ClinicalPath Portal as having the ability to diagnose disease, prescribe treatment, or perform any other tasks that constitute the practice of providing medical care. The clinical information contained within the ClinicalPath Portal is intended as a supplement to, and not a substitute for, the knowledge, expertise, skill, and judgment of physicians, pharmacists and other healthcare professionals involved with patient care at User/Authorized User facilities. CONFIDENTIAL AND PROPRIETARY. NOT FOR DISTRIBUTION.

ELSEVIER

User/Authorized User acknowledges that the ClinicalPath Portal is intended to be utilized as an information management tool only, and that Elsevier has not represented the ClinicalPath Portal as having the ability to diagnose disease, prescribe treatment, or perform any other tasks that constitute the practice of providing medical care. The clinical information contained within the ClinicalPath Portal is intended as a supplement to, and not a substitute for, the knowledge, expertise, skill, and judgment of physicians, pharmacists and other healthcare professionals involved with patient care at User/Authorized User facilities. CONFIDENTIAL AND PROPRIETARY. NOT FOR DISTRIBUTION.